###begin article-title 0
Variable expression of cysteinyl leukotriene type I receptor splice variants in asthmatic females with different promoter haplotypes
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 139 146 139 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYSLTR1</italic>
###xml 348 350 348 350 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 387 395 387 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYSLTR1 </italic>
###xml 99 104 <span type="species:ncbi:9606">Human</span>
Cysteinyl leukotrienes are potent inflammatory mediators implicated in the pathogenesis of asthma. Human cysteinyl leukotriene receptor 1 (CYSLTR1) gene contains five exons that are variably spliced. Within its promoter few polymorphisms were described. To date, there has been no evidence about the expression of different splice variants of CysLT1 in asthma and their association with CYSLTR1 promoter polymorphisms.
###end p 2
###begin p 3
###xml 46 48 46 48 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 120 128 120 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYSLTR1 </italic>
###xml 96 104 <span type="species:ncbi:9606">patients</span>
The goal of our study was to investigate CysLT1 alternative transcripts expression in asthmatic patients with different CYSLTR1 promoter haplotypes.
###end p 3
###begin p 4
###xml 317 325 317 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYSLTR1 </italic>
###xml 33 41 <span type="species:ncbi:9606">patients</span>
The study groups consisted of 44 patients with asthma, diagnosed according to GINA 2008 criteria and 18 healthy subjects. Genomic DNA and total RNA was extracted from peripheral blood mononuclear cells. Real-time PCR was performed with specific primers for transcript I [GenBank:] and II [GenBank:]. Fragments of the CYSLTR1 promoter were amplified by PCR and sequenced directly to identify four single nucleotide polymorphisms: C/T [SNP:rs321029], A/C [SNP:rs2637204], A/G [SNP:rs2806489] and C/T [SNP:rs7066737].
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 23 25 23 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 302 304 302 304 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 462 464 462 464 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 164 169 <span type="species:ncbi:9606">women</span>
###xml 277 282 <span type="species:ncbi:9606">women</span>
###xml 503 508 <span type="species:ncbi:9606">women</span>
The expression of CysLT1 transcript I and II in asthma did not differ from its expression in healthy control group. However, in major alleles homozygotic CAAC/CAAC women with asthma we found significantly higher expression of transcript I as compared to heterozygous CAAC/TCGC women in that loci. CysLT1 transcript I expression tended to negative correlation with episodes of acute respiratory infection in our asthmatic population. Moreover, expression of CysLT1 transcript II in CAAC/CAAC homozygotic women with asthma was significantly lower than in CAAC/CAAC healthy control females.
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 20 28 20 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYSLTR1 </italic>
###xml 97 99 97 99 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 153 155 153 155 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 126 134 <span type="species:ncbi:9606">patients</span>
Genetic variants of CYSLTR1 promoter might be associated with gender specific expression of CysLT1 alternative transcripts in patients with asthma. CysLT1 splice variants expression might also correlate with the susceptibility to infection in asthmatic population.
###end p 8
###begin title 9
Background
###end title 9
###begin p 10
###xml 77 78 77 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 382 383 382 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 384 385 384 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 471 472 471 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 473 474 473 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 592 593 592 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 594 595 594 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 688 689 688 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 770 771 770 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 772 773 772 773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 850 851 850 851 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 852 853 852 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 854 856 854 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 864 866 864 866 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2 </sub>
###xml 867 869 867 869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 870 872 870 872 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 904 906 904 906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 1052 1054 1052 1054 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 1230 1232 1230 1232 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 1529 1530 1529 1530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 1531 1533 1531 1533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 1534 1536 1534 1536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 1537 1539 1537 1539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 1547 1549 1547 1549 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 1604 1606 1604 1606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 1607 1609 1607 1609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 1678 1680 1678 1680 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 1808 1810 1808 1810 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 1868 1870 1868 1870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 2068 2070 2068 2070 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 2071 2073 2071 2073 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 2149 2157 2149 2157 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYSLTR1 </italic>
###xml 2217 2219 2217 2219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 2220 2222 2220 2222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 2409 2411 2409 2411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 2470 2478 2470 2478 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYSLTR1 </italic>
###xml 2539 2541 2539 2541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 2542 2544 2542 2544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 2545 2547 2545 2547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 2584 2586 2584 2586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 2684 2692 2684 2692 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYSLTR1 </italic>
###xml 2897 2905 2897 2905 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYSLTR1 </italic>
###xml 2975 2977 2975 2977 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 3121 3123 3121 3123 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 3226 3234 3226 3234 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYSLTR1 </italic>
###xml 3337 3339 3337 3339 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 1213 1218 <span type="species:ncbi:9606">human</span>
###xml 1591 1596 <span type="species:ncbi:9606">human</span>
###xml 2726 2731 <span type="species:ncbi:9606">women</span>
###xml 3150 3158 <span type="species:ncbi:9606">patients</span>
Asthma is a complex disease influenced by genetic and environmental factors [1], with highly variable clinical spectrum, but with the consistent presence of airway inflammation. Among many important inflammatory mediators involved in its pathogenesis are cysteinyl leukotrienes. They are potent lipid mediators derived from the lipooxygenase pathway of arachidonic acid metabolism [2,3]. They are products of activated eosinophils, mast cells, basophils and macrophages [3,4]. Originally identified as potent mediators of bronchoconstriction, mucus secretion, and airway hyperresponsiveness [2,5], they are now also described as important factors of innate and adaptive immune responses [6], as well as in the effector phase of inflammation, tissue repair and fibrosis [7,8]. So far, three cysteinyl leukotrienes receptors have been identified: CysLT1[9,10], CysLT2 [11-13] and recently described GPR17 [14]. All of them are seven transmembrane-spanning receptors that couple to G proteins (GPCR) and activate various intracellular signaling pathways [15]. The distribution of these three types of CysLTs receptors is diverse and depends on the cells and tissues as well as on the pathophysiologic conditions. In human lungs CysLT1 protein was demonstrated in the smooth muscle cells at all levels of the respiratory tract, interstitial lung macrophages and in the epithelial cells as well as in infiltrating inflammatory cells such as monocytes/macrophages, mast cells, eosinophils, CD 34+ cells, neutrophils and B lymphocytes [9,10,16,17]. CysLT1 mRNA was observed in normal and asthmatic human lungs [10,16]. However, recent studies have shown a significant increase in CysLT1 positive cells in the bronchi of stable asthmatics in comparison to healthy, non smoking controls and further elevation of CysLT1 mRNA and protein in acute severe exacerbations of asthma [18]. Nevertheless, response to leukotriene antagonists (LTRA) in asthma is known to be variable and it still has not been determined which of the phenotypes benefits most from this type of treatment [19-21]. Moreover, there is still a discrepancy about the precise location of the CYSLTR1 promoter region and the exon/intron structure of this gene [22,23]. Therefore, there is a possibility that at least two alternative promoters exist and might initiate different transcripts of the receptor gene in various pathophysiological conditions [22]. Furthermore, functional and case-control studies of the CYSLTR1 gene contribution to asthma have shown inconsistent results [22,24,25]. We have also previously observed [26] that some clinical features of severe asthma were associated with the minor [TCGC] haplotype of CYSLTR1 promoter SNPs in severe asthmatic women. However, we have found no significant differences in gene reporter activity among all tested promoter SNPs constructs. Therefore in this study we hypothesized that CYSLTR1 gene promoter polymorphisms might influence on the expression of CysLT1 alternative transcripts, which might further influence on the course of the disease. To test this hypothesis, we analyze the expression of CysLT1 alternative transcripts in patients with asthma and in healthy control group with the relevance to the CYSLTR1 gene promoter polymorphisms. We demonstrate here that there is no difference in the expression of CysLT1 alternative transcripts between asthmatic and healthy population analyzed without focus on genetic background and sex stratification.
###end p 10
###begin p 11
###xml 43 45 43 45 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 83 88 <span type="species:ncbi:9606">women</span>
However, there is a difference in the CysLT1 alternative transcripts expression in women with asthma with different promoter haplotypes. Furthermore, we also demonstrate that the expression of certain splice variants correlates with the episodes of acute infections.
###end p 11
###begin title 12
Materials
###end title 12
###begin title 13
Study population
###end title 13
###begin p 14
###xml 434 436 434 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 848 850 848 850 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 1591 1593 1589 1591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 1687 1689 1685 1687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 2208 2211 2206 2209 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">e.g</italic>
###xml 22 30 <span type="species:ncbi:9606">patients</span>
###xml 609 617 <span type="species:ncbi:9606">patients</span>
###xml 1205 1212 <span type="species:ncbi:9606">patient</span>
###xml 1433 1440 <span type="species:ncbi:9606">patient</span>
###xml 1495 1503 <span type="species:ncbi:9606">patients</span>
###xml 1904 1912 <span type="species:ncbi:9606">patients</span>
###xml 2179 2187 <span type="species:ncbi:9606">patients</span>
The study involved 44 patients with persistent asthma randomly selected from asthmatic group treated in the Outpatient Unit of the Department of Immunology, Rheumatology and Allergy in Lodz, Poland. The sex matched healthy individuals group consisted of 18 unrelated, non-atopic subjects with a negative family history of allergy and asthma. Asthma was defined by a specialist of respiratory diseases according to GINA 2008 criteria [27]. Atopy was defined as one or more positive reactions in the skin prick tests with the battery of inhaled allergens. The aspirin intolerant asthma phenotype was defined in patients having a proven history of asthma aggravation on exposure to aspirin/NSAIDs and a positive response in a lysine-aspirin bronchoprovocation test. Exacerbations were defined as acute worsening of asthma symptoms with decrease of FEV1 or PEF >/= 20% diagnosed by the doctor and put in the case history as a word "exacerbation", with hospitalization or urgent visit for asthma or stated aggravation of asthma symptoms requiring at least doubling the dose of ICS or addition or periodic increase of oral GCS. Episodes of acute respiratory tract infection were defined as acute aggravation of patient's health with fever, yellow sputum and need for antibiotic usage with or without asthma exacerbation. Nocturnal dyspnoea was characterised and stated in the case history by the doctor according to the interview with the patient. Chronic rhinosinusitis was diagnosed on the basis of patients' symptoms and CT scans. Allergic rhinitis was defined according to ARIA 2008 criteria [28]. GERD was diagnosed according to American College of Gastroenterology 2005 recommendations [29]. The doses of ICS were calculated as the budesonide equivalent within the whole period of observation in the Outpatient Unit and divided by the number of observation days and presented as micrograms per day. Some patients received ICS by nebulization. The doses of systemic GCS were calculated as a prednisone equivalent. GCS, montelukast and zafirlukast were also divided by the number of whole days of observation and presented as milligrams per day. These drugs were prescribed to the patients for certain periods e.g. 2-3 weeks in regards of GCS in decreasing dosage in case of exacerbation or 3-4 months in regards of leukotriene receptor antagonists in case of worse asthma control and there were periods free of certain drugs. Therefore, median dose of certain drug per day includes periods without this drug usage. Thus, the dose of the drug could be lower than available and commonly used doses.
###end p 14
###begin p 15
###xml 21 29 <span type="species:ncbi:9606">patients</span>
Clinical features of patients were analysed retrospectively over the whole period of observation using individually self-created database software, with the possibility of calculations of studied variables.
###end p 15
###begin p 16
###xml 61 62 61 62 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
Characteristics of the studied groups are presented in Table 1. The study was approved by the Ethics Committee of the Medical University of Lodz and informed consent was obtained from every subject prior to the study.
###end p 16
###begin p 17
Characteristics of the studied groups
###end p 17
###begin p 18
Variables are shown as median and range or percentage. n.a. - non applicable.
###end p 18
###begin title 19
Genomic DNA Preparation and Single Nucleotide Polymorphisms (SNPs) Genotyping
###end title 19
###begin p 20
Genomic DNA was extracted from peripheral blood mononuclear cells of studied subjects using Genomic Maxi AX (A&A, Gdansk, Poland). A 633 bp fragment containing [SNP:rs321029] C/T, [SNP:rs2637204] A/C was obtained with the following primers: 5'-AGCCTTTTCCTTTCTGGTTC-3'(forward) and 5'-TCACCATCACCACCACAATC-3'(reverse) (Tib Molbiol, Poznan, Poland). A 602 bp fragment containing the [SNP:rs2806489] A/G and [SNP:rs70667337] C/T was amplified with the following primers: 5'-GAGCAGGGCACATTTGCTAG-3'(forward) and 5'-GCAAGCCCAGTCATTCCAGA-3'(reverse) (Tib Molbiol). Primer design and optimization of annealing temperatures were performed with MacVector software (Oxford Molecular Group, Madison, WI). PCR condition were as follows: initial 5 min at 95degreesC followed by 35 cycles of 30 s at 94degreesC, 30 s at 58degreesC, 45 s at 72degreesC and 7 min at 72degreesC. The PCR reactions were performed in Biometra T3 thermocycler (Biometra, Gottingen, Germany). These PCR fragments were purified with Clean-Up (A&A) and labeled using fluorescently labeled dye terminators technique (Applied Biosystems, Foster City, CA) with specific nested primers. To analyze sequence including rs321029 and rs2637204, following primers were used: 5'-ACATCAAAGTGCTGCCCCAG-3' and for sequence including rs2806489 and rs70667337: 5'-GGAACCAGAAAGGAAAAGGC-3' (Eurogentec, Polgen, Lodz, Poland) and appropriate primers from PCR in case of samples from female subjects which were sequenced in both directions. Second purification step was performed using ExTerminator kit (A&A). All sequencing reactions were performed in ABI Prism 310 capillary sequencer (Applied Biosystems).
###end p 20
###begin title 21
Real-Time PCR analysis of alternative transcripts expression
###end title 21
###begin p 22
###xml 922 924 904 906 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 1045 1047 1027 1029 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 1381 1383 1363 1365 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 1710 1712 1668 1670 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 1892 1899 1832 1839 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">versus </italic>
###xml 2130 2132 2070 2072 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
Peripheral blood mononuclear cells were isolated from the blood using Histopaque 1077 (Sigma-Aldrich, Poland) density gradient centrifugation. Total RNA was isolated from peripheral blood mononuclear cells using the Total RNA Extraction Kit (A&A) according to manufacturer's protocol in the presence of RQ1 RNase-Free DNase (Promega, Madison, WI, USA). Total RNA (2 mug) was reverse-transcribed using the random hexamers and ImProm-IItrade mark reverse transcription system (Promega) in a volume of 25 mul at 37degreesC for 90 min. All real-time PCR reactions were optimized to obtain the best amplification kinetics. Amplification reactions were performed in a final volume of 20 mul using qPCRTM Core Kit for SybrTM Green I w/o dUTP (EUROGENTEC, Seraing, Belgium), 250 nM primers and 25 ng cDNA template per reaction. Nuclease free water was used as a no-template control. The following primer pairs were used: for CysLT1 transcript I [GenBank:]: forward 5'-AACGCAAAAGGACAGTAAACTGTG-3' and reverse 5'-ATCAATGCCTTTTACGGTGTAATATTAG-3'; for CysLT1 transcript II [GenBank:]: forward 5'-TCGAATTTACTGAAGACTTGGAGCTTGCTTC-3' and reverse 5'-TCTCTACGAATGTCTGCTTTGTGCCTGC-3', for RPS17: 5'-ACCCCAATGTCAAGGAGATCAAGGTCCTG-3' and 5'-TCGGCAGCCAGCTCGTGAGTAATG-3', for histone H3A - H3F3A: 5'-AGGACTTTAAAAGATCTGCGCTTCCAGAG-3' and 5'-ACCAGATAGGCCTCACTTGCCTCCTGC-3'. Gene expression levels of CysLT1 transcript I and II and two reference transcripts: RPS17, and H3F3A were tested using the Rotor-Gene 3000 Real-Time DNA analysis system (Corbett Research, Australia). Cycling conditions: 1 cycle at 95degreesC for 10 min, 40 cycles at 95degreesC for 30 s, 56degreesC for 15 s (CysLTR1 transcript I) or 65degreesC for 15 s (CysLT1 transcript II) or 64degreesC for 15 s (RPS17) or 65degreesC for 15 s (H3F3A), and 72degreesC for 30 s. The relative expression was based on the expression ratio of the target gene versus reference genes (RPS17 and H3F3A). To calculate the relative expression ratios of single samples a mathematical model was used which included an efficiency correction for the real-time PCR efficiency of the individual transcripts [30]. Relative expression was calculated using REST (Corbett Research, Australia) software with the two reference genes mentioned above. Each experiment was conducted in triplicate.
###end p 22
###begin title 23
Statistical analysis
###end title 23
###begin p 24
###xml 635 637 633 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 729 734 727 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 757 759 755 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 766 775 764 773 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">post-hoc </italic>
The data from the study were analyzed using Statistica (v. 6.0; StatSoft, Tulsa, OK). The distribution of all examined variables was checked for normality. Because of the deviation from normal distribution, in the analysis of alternative transcripts expression U-Mann-Whitney test was performed to analyze differences between variables. Data are expressed as mean relative expression +/- SEM. Relationship between alternative transcripts expression and studied asthmatic features were evaluated utilizing Spearman's rank correlation test. Haplotype frequencies and linkage disequilibria were estimated using the HaploView 4.0 program [31]. Haplotypes of each individual were inferred by using the algorithm developed by Stephens et al. (PHASE version 2.1) [32]. The post-hoc analysis of the quantitative variables with the Bonferroni correction was performed to account for multiple testing.
###end p 24
###begin title 25
Results
###end title 25
###begin title 26
Study population
###end title 26
###begin p 27
###xml 35 37 35 37 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 177 178 177 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 252 253 252 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
###xml 375 377 375 377 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 564 566 560 562 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 847 850 839 842 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs </italic>
###xml 75 83 <span type="species:ncbi:9606">patients</span>
###xml 297 305 <span type="species:ncbi:9606">patients</span>
###xml 789 797 <span type="species:ncbi:9606">patients</span>
###xml 838 846 <span type="species:ncbi:9606">patients</span>
We analyzed the expression of CysLT1 alternative transcript I and II in 44 patients with asthma and 18 healthy controls. Characteristics of study populations are shown in Table 1. Haplotype distributions in both analyzed populations are shown in Table 2. CAAC and TCGC were dominant haplotypes in patients with asthma and in healthy controls. The relative expression of CysLT1 transcript I in peripheral blood mononuclear cells was similar in asthma (22.87 +/- 5.93) and in healthy control group (26.23 +/- 12.98) (p > 0.05). Moreover, relative expression of CysLT1 transcript II was lower than transcript I and also similar in asthma (5.05 +/- 0.84) and in controls (8.54 +/- 2.41) (p > 0.05). Furthermore, the expression of these two splice variants did not differ either between female patients with asthma and female controls or male patients vs male controls.
###end p 27
###begin p 28
Haplotypes frequency in the asthmatic population (n = 44) and healthy subjects (n = 18)
###end p 28
###begin title 29
Alternative Transcripts-Haplotype Association Study
###end title 29
###begin p 30
###xml 54 56 54 56 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 121 129 121 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYSLTR1 </italic>
###xml 217 219 217 219 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 475 476 475 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
###xml 712 716 710 714 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cor </sub>
###xml 769 773 765 769 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cor </sub>
###xml 894 895 886 887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1</xref>
###xml 897 898 889 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2</xref>
###xml 549 554 <span type="species:ncbi:9606">women</span>
###xml 820 825 <span type="species:ncbi:9606">women</span>
###xml 987 990 <span type="species:ncbi:9606">men</span>
###xml 1053 1061 <span type="species:ncbi:9606">patients</span>
We hypothesized that the different expression of CysLT1 alternative transcripts might depend on the polymorphisms in the CYSLTR1 gene promoter region. Thus, we performed an analysis concerning association of the CysLT1 splice variants expression with the haplotypes in each locus within the whole study population. We analyzed the differences between the two main haplotypes CAAC and TCGC as they accounted for nearly 90% of the studied populations, which was shown in Table 2. The other haplotypes were too rare to perform appropriate analysis. In women with asthma who are homozygotes in major alleles in each analyzed locus CAAC/CAAC we found significantly higher expression of transcript I 37.22 +/- 14.11 (pcor = 0.0169) and transcript I/II 13.38 +/- 6.10 ratio (pcor = 0.009) as compared to heterozygous CAAC/TCGC women in that loci, 4.08 +/- 1.06 and 1.49 +/- 0.65, respectively (Figure 1, 2). We did not observe any differences in alternative transcripts expression in asthmatic men with different promoter genotypes or in both sexes of healthy patients.
###end p 30
###begin p 31
###xml 5 7 5 7 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 75 83 75 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYSLTR1 </italic>
###xml 0 93 0 93 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CysLT<sub>1 </sub>transcript I relative expression in women with asthma with two main <italic>CYSLTR1 </italic>haplotypes</bold>
###xml 43 48 <span type="species:ncbi:9606">women</span>
CysLT1 transcript I relative expression in women with asthma with two main CYSLTR1 haplotypes. Data are expressed as dots. Horizontal line represents mean. Asterisk indicates p < 0.05.
###end p 31
###begin p 32
###xml 5 7 5 7 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 84 92 84 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYSLTR1 </italic>
###xml 0 102 0 102 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CysLT<sub>1 </sub>transcript I/II relative expression ratio in women with asthma with two main <italic>CYSLTR1 </italic>haplotypes</bold>
###xml 52 57 <span type="species:ncbi:9606">women</span>
CysLT1 transcript I/II relative expression ratio in women with asthma with two main CYSLTR1 haplotypes. Data are expressed as dots. Horizontal line represents mean. Asterisk indicates p < 0.05.
###end p 32
###begin title 33
CysLTR1 alternative transcripts correlations
###end title 33
###begin p 34
###xml 38 40 38 40 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 120 121 120 121 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 370 372 370 372 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 443 447 443 447 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cor </sub>
###xml 465 466 465 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">3</xref>
###xml 497 499 497 499 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
We analyzed here correlations of CysLT1 alternative transcripts expression with different features of asthma such as FEV1, PEF, exacerbations, episodes of acute infection, hospitalization for asthma, nocturnal dyspnoe and intake of ICS, systemic GCS and LTRA in the whole asthmatic population. We observed weak but statistically significant negative correlation of CysLT1 transcript I expression with episodes of acute infection (R = - 0,52, pcor = 0.0009) (Figure 3). Relative expression of CysLT1 transcript II did not correlate with any of studied asthmatic features.
###end p 34
###begin p 35
###xml 20 22 20 22 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 0 125 0 125 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Correlation of CysLT<sub>1 </sub>transcript I relative expression with the episodes of acute infection in the whole asthmatic population</bold>
###xml 184 188 184 188 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cor </sub>
Correlation of CysLT1 transcript I relative expression with the episodes of acute infection in the whole asthmatic population. Spearman's rank correlation coefficient was R = - 0.52, pcor = 0.0009.
###end p 35
###begin title 36
Alternative Transcripts-Haplotype-Phenotype Association Study
###end title 36
###begin p 37
###xml 50 52 50 52 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 321 323 321 323 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 481 485 477 481 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cor </sub>
###xml 502 503 498 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">4</xref>
###xml 548 550 544 546 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 141 149 <span type="species:ncbi:9606">patients</span>
###xml 362 367 <span type="species:ncbi:9606">women</span>
We analyzed here if there are differences in CysLT1 splice variants I and II expression in carriers of the same haplotypes between asthmatic patients and healthy controls with subsequent sex stratification. Again, we took into consideration two main haplotypes CAAC and TCGC. We observed that relative expression of CysLT1 transcript II in CAAC/CAAC homozygotic women with asthma (3.86 +/- 1.06) was significantly lower than in CAAC/CAAC healthy control females (14.48 +/- 6.90) (pcor = 0.019) (Figure 4). There were no differences in case of CysLT1 transcript I expression in either of analyzed configurations.
###end p 37
###begin p 38
###xml 6 8 6 8 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 0 75 0 75 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CysLTR<sub>1 </sub>transcript II expression in CAAC/CAAC asthmatic and control females</bold>
CysLTR1 transcript II expression in CAAC/CAAC asthmatic and control females. Data are expressed as dots. Horizontal line represents mean. Asterisk indicates p < 0.05.
###end p 38
###begin title 39
Discussion
###end title 39
###begin p 40
###xml 54 56 54 56 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 268 274 268 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al </italic>
###xml 348 349 348 349 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 528 530 528 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 565 567 565 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 650 652 650 652 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 665 667 665 667 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 852 854 852 854 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 1341 1343 1341 1343 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 1503 1505 1503 1505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 1555 1557 1555 1557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 140 148 <span type="species:ncbi:9606">patients</span>
###xml 929 937 <span type="species:ncbi:9606">patients</span>
###xml 1394 1402 <span type="species:ncbi:9606">patients</span>
Here we showed that there were no differences in CysLT1 alternative transcripts expression in the blood mononuclear cells between asthmatic patients and controls, when they were evaluated as genetically homogeneous populations and without sex stratification. Figueroa et al found that 20% of peripheral blood leukocytes showed the presence of CysLT1. These are cells of particular relevance to asthma and atopy, such as monocytes/macrophages, eosinophils, pregranulocytic CD34+ cells, neutrophils, and subsets of B lymphocytes [33] and probably also T lymphocytes [17]. According to our best knowledge there has been no data published comparing CysLT1 mRNA or CysLT1 alternative transcripts expression in peripheral blood mononuclear cells between asthmatic and healthy subjects. There might be a few reasons of lack of differences in the overall CysLT1 mRNA expression at least in the blood mononuclear cells. First of all, our patients were in the stable period of the disease, without a trace of exacerbation in the moment of blood collection. Therefore, inflammation might be present only locally in the bronchi, not in the peripheral blood, mainly because of the persistent influx of inflammatory cells from the blood to the bronchi. Zhu and colleagues found that there is an increase of distinct inflammatory cells expressing the CysLT1 receptor in the bronchial mucosa of mild asthmatic patients as compared to healthy subjects and further increase when there is a severe exacerbation of asthma [18]. However they did not analyze peripheral blood [18].
###end p 40
###begin p 41
###xml 95 103 95 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYSLTR1 </italic>
###xml 227 229 227 229 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 454 456 454 456 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 537 538 537 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1</xref>
###xml 540 541 540 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2</xref>
###xml 683 691 683 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYSLTR1 </italic>
###xml 725 727 725 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 1376 1378 1376 1378 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 1611 1612 1611 1612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">3</xref>
###xml 1643 1645 1643 1645 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 1911 1913 1911 1913 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 1934 1935 1934 1935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 2124 2126 2124 2126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 2127 2129 2127 2129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
###xml 2291 2293 2291 2293 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 2321 2323 2321 2323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B36">36</xref>
###xml 2512 2514 2512 2514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 589 594 <span type="species:ncbi:9606">women</span>
###xml 628 631 <span type="species:ncbi:9606">men</span>
###xml 1582 1590 <span type="species:ncbi:9606">patients</span>
###xml 1859 1867 <span type="species:ncbi:9606">patients</span>
###xml 2466 2474 <span type="species:ncbi:9606">patients</span>
Nevertheless, it might also confirm our main hypothesis of indirect promoter SNPs influence on CYSLTR1 gene transcription and/or alternative splicing in a sex related manner. This might further correlate with the level of CysLT1 protein expression and finally with the disease phenotype. Several lines of evidence support this hypothesis. First of all, we found that heterozygotic females CAAC/TCGC with asthma had significantly lower expression of CysLT1 transcript I as compared to major female asthmatic homozygotes CAAC/CAAC (Figure 1, 2). This correlation was not observed in healthy women neither in asthmatic and healthy men. In our previous study on the association of these CYSLTR1 promoter SNPs with severe asthma [26] in the population of 93 severe asthmatics, 110 non-severe asthmatics and 100 healthy controls we showed that heterozygotic CAAC/TCGC females with severe asthma had significantly more episodes of infection per year, more exacerbations per year, more hospitalizations for asthma per year, and they used more ICS than homozygotic female carriers of the main haplotype CAAC/CAAC. However, we found no evidence on the influence of these promoter SNPs on the gene expression by means of reporter gene studies. Therefore, our current findings might at least partially link this association with the functional effects. Moreover, we showed here that CysLT1 alternative transcripts expression might slightly affect factors associated with the course of asthma. We have observed the weak tendency that the more episodes of acute respiratory infection per year in patients with asthma (Figure 3) the lower expression of CysLT1 transcript I. However, the feeble distribution of data limits any potential conclusions. Nevertheless, it could indicate on the probability of impaired innate and afferent mechanisms of acquired immune response in patients with asthma, probably through altered CysLT1 receptor expression [6]. CysLTs and their receptors were proven to be critical determinants of dendritic cells homing to regional lymph nodes and the repertoire of cytokines required to induce T cell responses [34,35]. It was shown that maturation of dendritic cells with LPS, a major endotoxin of Gram-negative bacteria and a classic Toll-like receptor 4 agonist, reduced CysLT1 receptor expression by 50% [36]. Moreover, generation of leukotrienes from white blood cells was enhanced during sepsis, and further increased after stimulation but only in patients who survived this massive infection [37]. This data might indicate the importance of leukotrienes and their receptors not only in the development of chronic inflammation in asthma but also in episodes of acute respiratory infections, which are one of the most important determinants of asthma exacerbations.
###end p 41
###begin p 42
###xml 430 432 430 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38">38</xref>
###xml 433 435 433 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B40">40</xref>
###xml 532 534 532 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B41">41</xref>
###xml 535 537 535 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B42">42</xref>
###xml 664 666 664 666 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 763 764 763 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">4</xref>
###xml 914 918 914 918 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">e. g</italic>
###xml 1016 1024 1016 1024 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYSLTR1 </italic>
###xml 1162 1170 1162 1170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYSLTR1 </italic>
###xml 1195 1197 1195 1197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 1198 1200 1198 1200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 1216 1218 1216 1218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 1256 1264 1256 1264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYSLTR1 </italic>
###xml 1289 1291 1289 1291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 1495 1497 1495 1497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B43">43</xref>
###xml 1618 1621 1618 1621 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">e.g</italic>
###xml 1630 1632 1630 1632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B44">44</xref>
###xml 1675 1677 1675 1677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B45">45</xref>
###xml 1861 1863 1861 1863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B46">46</xref>
###xml 1891 1893 1891 1893 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 2189 2191 2189 2191 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 2225 2227 2225 2227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 2372 2380 2372 2380 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYSLTR1 </italic>
###xml 2477 2479 2477 2479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 2501 2509 2501 2509 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYSLTR1 </italic>
###xml 2942 2944 2942 2944 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 3001 3007 3001 3007 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al </italic>
###xml 3008 3010 3008 3010 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 3297 3299 3297 3299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B47">47</xref>
###xml 3300 3302 3300 3302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B48">48</xref>
###xml 3499 3501 3499 3501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B49">49</xref>
###xml 332 359 <span type="species:ncbi:12814">respiratory syncytial virus</span>
###xml 641 646 <span type="species:ncbi:9606">women</span>
###xml 749 754 <span type="species:ncbi:9606">women</span>
###xml 1922 1927 <span type="species:ncbi:9606">human</span>
###xml 3166 3171 <span type="species:ncbi:9606">human</span>
###xml 3491 3497 <span type="species:ncbi:9606">humans</span>
Episodes of acute respiratory infection in our study population by means of symptoms and reaction to antibiotic treatment fulfilled the definition of bacterial infection. The limitation of this definition is lack of exact evidence on bacterial or viral involvement. On the other hand, it has been proven that viral infections, like respiratory syncytial virus or parainfluenza virus, increase the level of cysteinyl leukotrienes [38-40] and that antileukotriene drugs alleviate symptoms of viral upper respiratory tract infections [41,42]. The last but not least argument for our initial hypothesis is that we have noticed that in CAAC/CAAC women with asthma CysLT1 transcript II is differentially expressed as compared to CAAC/CAAC healthy control women (Figure 4). Together with our previous findings that promoter SNPs did not influence its basal activity, these data might suggest that there are other factors e. g. splicing factors, sex hormones or the effects of some inflammatory cytokines that influence the CYSLTR1 gene transcription and/or splicing. It stays in agreement with primarily contradictory findings of our and other groups. Minor alleles of CYSLTR1 promoter SNPs increased [24,25] or decreased [22] or demonstrated no influence on the CYSLTR1 basic promoter activity [26]. Nowadays, there is an emerging consensus suggesting that splicing is in most cases initiated cotranscriptionally and that introns are removed while the nascent transcript is still tethered to the DNA [43]. Some transcriptional coregulators, brought to the promoters by transcription factors, either harbor splicing activity e.g. hnRNP [44] or interact with spliceosome components [45]. Inversely, some proteins like SKIP described initially as RNA-binding splicing factors were later shown to be present at promoters and/or to function as transcriptional regulators [46]. Four different mRNA CysLT1 transcripts were observed in human cells, with the dominant expression of transcript I in both unstimulated and IL-4 stimulated cells and far less abundant expression of transcript II. Transcript III and IV were found only in THP1 cell lines. However, the role of alternative transcripts of CysLT1 receptor has not been elucidated [23]. They all form the same protein structure as the coding region and ORF is included in the fifth exon, present in each transcript. The putative CYSLTR1 promoter was found to contain two STAT6 consensus response elements, GATA and AP1 binding sites [23]. Four analyzed here CYSLTR1 promoter SNPs do not change any known transcription factor binding sites, but they might influence on the splicing binding factors. Altered ratio of main transcripts I and II might further influence on the expression status of structurally unchanged receptor protein, not only in blood leukocytes but also in inflammatory infiltration of the bronchi. This subsequently could correlate with the phenotype. Elevated expression of CysLT1 plays a role in asthma and its exacerbation as shown Zhu et al [18]. Alternative splicing of pre mRNA represents a widespread mechanism for increasing variability of eukaryotic gene expression and has been associated with human pathologies, such as cancer, Alzheimer's, amyotrophic lateral sclerosis, ataxia teleangiectasia, cystic fibrosis, and other [47,48]. For instance, non functional alpha subunit of the epithelial sodium channel alternatively spliced forms have been proposed to serve as negative regulatory components for its activity in humans [49].
###end p 42
###begin p 43
###xml 258 260 258 260 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 580 582 580 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B50">50</xref>
###xml 651 657 651 657 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al </italic>
###xml 865 867 865 867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B51">51</xref>
###xml 970 972 966 968 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B51">51</xref>
###xml 1139 1141 1135 1137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B52">52</xref>
###xml 1191 1193 1187 1189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B53">53</xref>
###xml 1262 1264 1258 1260 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 1331 1339 1327 1335 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYSLTR1 </italic>
###xml 1445 1447 1441 1443 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 1541 1543 1537 1539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B54">54</xref>
###xml 325 328 <span type="species:ncbi:9606">men</span>
###xml 501 509 <span type="species:ncbi:9606">patients</span>
###xml 561 566 <span type="species:ncbi:9606">women</span>
###xml 575 578 <span type="species:ncbi:9606">men</span>
Finally, our previous and current data indicated the gender differences in cysteinyl leukotrienes and their receptors metabolic pathways. Female sex and a certain haplotype might be a risk factor of the disease. Lack of the TCGC haplotype effect on the CysLT1 alternative transcripts expression in both asthmatic and healthy men might suggest an additional effect of sex hormones or some behavioral/environmental differences. Recently, it has been shown in the large European multi-centered cohort of patients that severe asthma occurs four times more often in women that in men [50]. Moreover, in accordance of our observations very recently Pergola et al showed higher expression of 5-LO, 15-H(P)ETE and CysLTs in stimulated whole blood and neutrophils in females comparing to males accompanied with the differences in 5-LO cellular localization and trafficking [51]. These effects were further abolished by male hormones testosterone and 5-alpha-dihydrotestosterone [51]. Moreover, it has been shown that estradiol modulates the pulmonary influx of inflammatory cells, increases generation of IL-4 and mediates mast cell degranulation [52] while progesterone upregulates IL-4 production [53]. All of these effects might increase the number of cells with CysLT1 receptor in the bronchial mucosa of female subjects. Expression of CYSLTR1 gene may be also affected by exposure to different proinflammatory cytokines. It has been shown that CysLT1 may be upregulated in different cells by proasthmatic cytokines such as IL-4, IL-5 and IL-13 [54] and the influence of analyzed haplotypes on gene expression and alternative splicing may only be present under specific inflammatory conditions.
###end p 43
###begin p 44
###xml 77 85 77 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYSLTR1 </italic>
###xml 160 162 160 162 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 279 287 279 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYSLTR1 </italic>
###xml 379 381 379 381 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
In summary, still little is known about factors involved in the processes of CYSLTR1 transcription, alternative splicing, and their influence on the final CysLT1 receptor protein expression and further correlation with the asthma phenotype. However, our data suggest that indeed CYSLTR1 gene might be implicated in asthma pathogenesis at least by differential expression of CysLT1 alternative transcripts in various haplotypes and in sex-related manner, but the exact mechanisms remain to be clarified.
###end p 44
###begin title 45
Conclusion
###end title 45
###begin p 46
###xml 20 28 20 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYSLTR1 </italic>
###xml 97 99 97 99 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 141 143 141 143 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 114 122 <span type="species:ncbi:9606">patients</span>
Genetic variants of CYSLTR1 promoter might be associated with gender specific expression of CysLT1 transcripts in patients with asthma. CysLT1 splice variants expression might also correlate with the susceptibility to infection in asthmatic population.
###end p 46
###begin title 47
Authors' contributions
###end title 47
###begin p 48
###xml 354 362 <span type="species:ncbi:9606">patients</span>
MS participated in the study design, performed experiments, interpreted the data and wrote the manuscript. KWN and KS performed experiments and drafted the manuscript. AKB and RP contributed funding and materials to the study, helped to design the experiments, analyzed the data and critically revised the manuscript adding important issues. MC enrolled patients to the study, participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.
###end p 48
###begin title 49
Acknowledgements
###end title 49
###begin p 50
This work was supported by the Medical University of Lodz grants 502-19-686 and 503-0149-3 and Polish Government grants N N401 224834 and N401 191 32/4009. Authors have no relationships to declare.
###end p 50
###begin article-title 51
Severe asthma in adults: what are the important questions?
###end article-title 51
###begin article-title 52
Prostaglandins and leukotrienes: advances in eicosanoid biology
###end article-title 52
###begin article-title 53
###xml 108 113 <span type="species:ncbi:9606">human</span>
Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases
###end article-title 53
###begin article-title 54
Leukotriene C4 synthase. A pivotal enzyme in the biosynthesis of the cysteinyl leukotrienes
###end article-title 54
###begin article-title 55
Biological profile of leukotrienes C4 and D4
###end article-title 55
###begin article-title 56
Leukotrienes: underappreciated mediators of innate immune responses
###end article-title 56
###begin article-title 57
Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses
###end article-title 57
###begin article-title 58
Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling
###end article-title 58
###begin article-title 59
###xml 24 29 <span type="species:ncbi:9606">human</span>
Characterization of the human cysteinyl leukotriene CysLT1 receptor
###end article-title 59
###begin article-title 60
Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor
###end article-title 60
###begin article-title 61
###xml 24 29 <span type="species:ncbi:9606">human</span>
Characterization of the human cysteinyl leukotriene 2 receptor
###end article-title 61
###begin article-title 62
###xml 51 56 <span type="species:ncbi:9606">human</span>
Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist
###end article-title 62
###begin article-title 63
###xml 62 67 <span type="species:ncbi:9606">human</span>
The molecular characterization and tissue distribution of the human cysteinyl leukotriene CysLT(2) receptor
###end article-title 63
###begin article-title 64
The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor
###end article-title 64
###begin article-title 65
###xml 44 49 <span type="species:ncbi:9606">human</span>
Leukotriene D(4) induces gene expression in human monocytes through cysteinyl leukotriene type I receptor
###end article-title 65
###begin article-title 66
###xml 61 66 <span type="species:ncbi:9606">human</span>
Expression of the cysteinyl leukotriene 1 receptor in normal human lung and peripheral blood leukocytes
###end article-title 66
###begin article-title 67
###xml 49 54 <span type="species:ncbi:9606">human</span>
Levels of cysteinyl leukotriene receptor mRNA in human peripheral leucocytes: significantly higher expression of cysteinyl leukotriene receptor 2 mRNA in eosinophils
###end article-title 67
###begin article-title 68
Localization and upregulation of cysteinyl leukotriene-1 receptor in asthmatic bronchial mucosa
###end article-title 68
###begin article-title 69
Pharmacogenetics of the 5-lipoxygenase biosynthetic pathway and variable clinical response to montelukast
###end article-title 69
###begin article-title 70
The anti-inflammatory effects of leukotriene-modifying drugs and their use in asthma
###end article-title 70
###begin article-title 71
Heterogeneity of therapeutic responses in asthma
###end article-title 71
###begin article-title 72
###xml 80 85 <span type="species:ncbi:9606">human</span>
Functional polymorphism and differential regulation of CYSLTR1 transcription in human airway smooth muscle and monocytes
###end article-title 72
###begin article-title 73
###xml 31 36 <span type="species:ncbi:9606">human</span>
Functional characterization of human cysteinyl leukotriene 1 receptor gene structure
###end article-title 73
###begin article-title 74
Cysteinyl leukotriene receptor 1 promoter polymorphism is associated with aspirin-intolerant asthma in males
###end article-title 74
###begin article-title 75
Determination of structure and transcriptional regulation of CYSLTR1 and an association study with asthma and rhinitis
###end article-title 75
###begin article-title 76
###xml 67 75 <span type="species:ncbi:9606">patients</span>
Promoter polymorphisms of cysteinyl leukotriene type 1 receptor in patients with different asthma phenotypes [abstract]
###end article-title 76
###begin article-title 77
Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA)
###end article-title 77
###begin article-title 78
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)
###end article-title 78
###begin article-title 79
Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease
###end article-title 79
###begin article-title 80
Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR
###end article-title 80
###begin article-title 81
Haploview: analysis and visualization of LD and haplotype maps
###end article-title 81
###begin article-title 82
A new statistical method for haplotype reconstruction from population data
###end article-title 82
###begin article-title 83
Expression of cysteinyl leukotriene synthetic and signalling proteins in inflammatory cells in active seasonal allergic rhinitis
###end article-title 83
###begin article-title 84
The leukotriene C(4) transporter MRP1 regulates CCL19 (MIP-3beta, ELC)-dependent mobilization of dendritic cells to lymph nodes
###end article-title 84
###begin article-title 85
###xml 62 68 <span type="species:ncbi:10090">murine</span>
Cysteinyl leukotrienes regulate dendritic cell functions in a murine model of asthma
###end article-title 85
###begin article-title 86
###xml 112 117 <span type="species:ncbi:9606">human</span>
Toll-like receptor agonists differentially regulate cysteinyl-leukotriene receptor 1 expression and function in human dendritic cells
###end article-title 86
###begin article-title 87
Functional analysis of eicosanoids from white blood cells in sepsis and SIRS
###end article-title 87
###begin article-title 88
###xml 38 41 <span type="species:ncbi:12814?0.7497633322814768">RSV</span>
Effect of secondhand cigarette smoke, RSV bronchiolitis and parental asthma on urinary cysteinyl LTE4
###end article-title 88
###begin article-title 89
###xml 83 86 <span type="species:ncbi:12814?0.7497633322814768">RSV</span>
###xml 107 111 <span type="species:ncbi:10090">mice</span>
Role of cysteinyl leukotrienes in airway inflammation and responsiveness following RSV infection in BALB/c mice
###end article-title 89
###begin article-title 90
Naturally occurring parainfluenza virus 3 infection in adults induces mild exacerbation of asthma associated with increased sputum concentrations of cysteinyl leukotrienes
###end article-title 90
###begin article-title 91
###xml 37 64 <span type="species:ncbi:12814">respiratory syncytial virus</span>
A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis
###end article-title 91
###begin article-title 92
Leukotriene receptor antagonists in virus-induced wheezing: evidence to date
###end article-title 92
###begin article-title 93
On the importance of being co-transcriptional
###end article-title 93
###begin article-title 94
###xml 166 173 <span type="species:ncbi:9031">chicken</span>
Heterogeneous nuclear ribonucleoprotein (hnRNP) K is a component of an intronic splicing enhancer complex that activates the splicing of the alternative exon 6A from chicken beta-tropomyosin pre-mRNA
###end article-title 94
###begin article-title 95
Regulation of RNA splicing by the methylation-dependent transcriptional repressor methyl-CpG binding protein 2
###end article-title 95
###begin article-title 96
###xml 2 7 <span type="species:ncbi:9606">human</span>
###xml 95 100 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A human splicing factor, SKIP, associates with P-TEFb and enhances transcription elongation by HIV-1 Tat
###end article-title 96
###begin article-title 97
Alternative splicing in disease and therapy
###end article-title 97
###begin article-title 98
###xml 69 74 <span type="species:ncbi:9606">human</span>
Alternative splicing: multiple control mechanisms and involvement in human disease
###end article-title 98
###begin article-title 99
Cloning and functional studies of splice variants of the alpha-subunit of the amiloride-sensitive Na+ channel
###end article-title 99
###begin article-title 100
The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma
###end article-title 100
###begin article-title 101
ERK-mediated regulation of leukotriene biosynthesis by androgens: a molecular basis for gender differences in inflammation and asthma
###end article-title 101
###begin article-title 102
###xml 50 53 <span type="species:ncbi:10116">rat</span>
Cellular recruitment and cytokine generation in a rat model of allergic lung inflammation are differentially modulated by progesterone and estradiol
###end article-title 102
###begin article-title 103
###xml 39 44 <span type="species:ncbi:9606">human</span>
Progesterone favors the development of human T helper cells producing Th2-type cytokines and promotes both IL-4 production and membrane CD30 expression in established Th1 cell clones
###end article-title 103
###begin article-title 104
Cysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: critical update and emerging trends
###end article-title 104

